Literature DB >> 26502087

Therapeutic advances in idiopathic pulmonary fibrosis.

G George1, U Vaid1, R Summer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26502087     DOI： 10.1002/cpt.283

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

1.  Clinical Pharmacology & Therapeutics: Past, Present, and Future.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

2.  Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis.

Authors:  A Tomaru; T Kobayashi; J A Hinneh; P Baffour Tonto; C N D'Alessandro-Gabazza; H Fujimoto; K Fujiwara; Y Takahashi; M Ohnishi; T Yasuma; K Nishihama; M Yoshino; K Takao; M Toda; T Totoki; Y Takei; K Yoshikawa; O Taguchi; E C Gabazza
Journal:  Gene Ther       Date:  2017-08-18       Impact factor: 5.250

3.  Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis.

Authors:  Hayley C Warsinske; Amanda K Wheaton; Kevin K Kim; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Front Pharmacol       Date:  2016-06-23       Impact factor: 5.810

Review 4.  Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Authors:  Bridget A Graney; Joyce S Lee
Journal:  Patient Relat Outcome Meas       Date:  2018-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.